Exhibit Number | ||
1. |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||
Date: November 29, 2019 | By: | /s/ Takashi Okubo | ||||
Takashi Okubo Global Head of Investor Relations |
![]() | ![]() |
Financial Highlights |
1.Business Performance |
Billion JPY | ||||||||||||
FY2018 H1 | FY2019 H1 | Change versus the same period of the previous fiscal year | ||||||||||
Revenue | 880.6 | 1,660.2 | 779.6 | 88.5 | % | |||||||
Cost of Sales | (231.3 | ) | (572.3 | ) | (341.0 | ) | 147.4 | % | ||||
Selling, General and Administrative expenses | (293.8 | ) | (462.5 | ) | (168.7 | ) | 57.4 | % | ||||
Research and Development expenses | (151.4 | ) | (230.4 | ) | (78.9 | 52.1 | % | |||||
Amortization and Impairment Losses on Intangible Assets Associated with Products | (48.3 | ) | (273.7 | ) | (225.4 | ) | 466.7 | % | ||||
Other Operating Income | 32.3 | 11.3 | (21.0 | ) | (65.0 | ) | % | |||||
Other Operating Expenses | (16.1 | ) | (82.4 | ) | (66.2 | ) | 410.4 | % | ||||
Operating Profit | 172.0 | 50.3 | (121.6 | ) | (70.7 | ) | % | |||||
Finance Income | 4.4 | 17.4 | 13.0 | 293.8 | % | |||||||
Finance Expenses | (19.6 | ) | (99.3 | ) | (79.6 | ) | 406.0 | % | ||||
Share of Profit of Investments Accounted for Using the Equity Method | 4.0 | 4.0 | 0.0 | 0.0 | % | |||||||
Profit (Loss) Before Income Tax | 160.8 | (27.6 | ) | (188.3 | ) | (117.1 | ) | % | ||||
Income Tax (Expenses) Benefit | (34.3 | ) | 60.8 | 95.1 | (277.4 | ) | % | |||||
Net Profit for the Period | 126.5 | 33.3 | (93.2 | ) | (73.7 | ) | % |
• | GI. In Gastroenterology, revenue was 341.6 billion JPY, a year-on-year increase of 89.5 billion JPY, or 35.5%. Growth was driven by ENTYVIO (for ulcerative colitis (UC) and Crohn’s disease (CD)), Takeda's top-selling product, with sales of 168.4 billion JPY, a year-on-year increase of 40.0 billion JPY, or 31.2%. Market share growth in the U.S. and in Europe was driven by further penetration of bio-naïve segment in UC and CD. In Japan, sales increased primarily as a result of the newly approved CD indication. Sales of TAKECAB (for acid-related diseases) were 35.0 billion JPY, an increase of 7.7 billion JPY, or 28.3% versus the same period of the previous year. The increase was driven by the expansion of new prescriptions in the Japanese market due to TAKECAB's efficacy in reflux esophagitis and the prevention of recurrence of gastric and duodenal ulcers during |
• | Rare Diseases. Products obtained through the acquisition of Shire contributed 327.2 billion JPY of revenue in Rare Diseases in the period. The biggest contributors in each therapeutic area were ELAPRASE in Rare Metabolic (for Hunter syndrome), ADVATE in Rare Hematology (for hemophilia A), and TAKHZYRO, a prophylaxis against Hereditary Angioedema, with sales of 35.5 billion JPY, 83.2 billion JPY, and 30.7 billion JPY, respectively. |
• | PDT Immunology. In PDT (Plasma-Derived Therapies) Immunology, revenue increased by 183.7 billion JPY compared to the same period of the prior year to 191.7 billion JPY, predominantly due to the addition of products obtained through the acquisition of Shire. Aggregate sales of immunoglobulin products were 146.5 billion JPY, and in particular, GAMMAGARD LIQUID (mainly for the treatment of primary immunodeficiency (PID) and multifocal motor neuropathy (MMN)) continued to build its position as a highly recognized intravenous immunoglobulin brand that is the standard of care treatment for PID and MMN in the U.S. Aggregate sales of albumin products including ALBUMIN GLASS and FLEXBUMIN (primarily used for hypovolemia and hypoalbuminemia) were 34.1 billion JPY and other PDT immunology products added 11.1 billion JPY of aggregate sales. |
• | Oncology. In Oncology, revenue was 214.8 billion JPY, a year-on-year increase of 16.4 billion JPY, or 8.3%. Sales of NINLARO (for multiple myeloma) were 38.3 billion JPY, an increase of 8.9 billion JPY, or 30.2%, versus the same period of the previous year, reflecting strong growth in global sales particularly in the U.S. and China. Additionally, sales of ADCETRIS (for malignant lymphomas) increased by 4.7 billion JPY, or 22.1%, to 25.8 billion JPY, reflecting strong growth in sales particularly in Japan where it has obtained an additional indication as a frontline treatment option for CD30-positive Hodgkin lymphoma. Revenue attributable to ALUNBRIG (for non-small cell lung cancer) increased by 1.1 billion JPY, or 48.3% to 3.4 billion JPY, as it continues to launch in European countries. Sales of VELCADE (for multiple myeloma) decreased by 1.3 billion JPY, or 1.9% compared to the same period of the previous year to 63.6 billion JPY, of which ex-US royalty income was 6.5 billion JPY, a year-on-year decrease of 5.1 billion JPY, or 44.1%, due to generic entry in Europe in late April. |
• | Neuroscience. In Neuroscience, revenue was 213.9 billion JPY, a year-on-year increase of 167.4 billion JPY, or 360.5%. This increase was largely attributable to the neuroscience portfolio obtained through the acquisition of Shire, including VYVANSE (for attention deficit hyperactivity disorder (ADHD)) which added 131.5 billion JPY of sales. TRINTELLIX (for major depressive disorder (MDD)) sales were 34.6 billion JPY, an increase of 7.5 billion JPY, or 27.6%, versus the same period of the previous year driven by increase in new patients and improved persistence on therapy. |
Revenue: | FY2018 H1 | FY2019 H1 | |||||||||
Japan | 274.2 | 31.1 | % | 299.4 | 18.0 | % | |||||
United States | 321.1 | 36.5 | % | 805.9 | 48.5 | % | |||||
Europe and Canada | 158.6 | 18.0 | % | 321.8 | 19.4 | % | |||||
Russia/CIS | 27.5 | 3.1 | % | 36.9 | 2.2 | % | |||||
Latin America | 34.7 | 3.9 | % | 75.8 | 4.6 | % | |||||
Asia (excluding Japan) | 51.9 | 5.9 | % | 83.9 | 5.1 | % | |||||
Other | 12.6 | 1.4 | % | 36.5 | 2.2 | % | |||||
Total | 880.6 | 100.0 | % | 1,660.2 | 100.0 | % |
* | Takeda's global operating expense reduction initiative with the aim of delivering annual margin improvements driven by reduced consumption, procurement initiatives and organizational optimization. |
FY2019 H1 | |
Underlying Revenue Growth*2 | -0.2% |
Underlying Core Operating Profit Margin | 32.2% |
Underlying Core EPS | 249.25 JPY |
• | GI. In Gastroenterology, underlying revenue increased by 8.9% compared to the same period of the previous year. Growth of ENTYVIO (+33.9%) and TAKECAB (+28.3%) fully absorbed the declines of off-patented products such as pantoprazole (-16.0%), lansoprazole (-28.1%), and LIALDA (-50.0%), which all faced further generic erosion. GATTEX/REVESTIVE (+17.0%) further reinforced our leadership in GI, partly benefitting from a pediatric indication obtained in the U.S. this year. |
• | Rare Diseases. In Rare Diseases, underlying revenue decreased by 10.5% due to higher competitive pressure and product recall of NATPARA. Competitive pressure was strong in Rare Hematology (-12.7%), as our hemophilia A products were especially impacted by competition, with significant decreases in ADVATE (-15.9%) and FEIBA (-24.4%), and lower revenue growth of ADYNOVATE (+5.4%), our extended half-life product. Declines in therapies for Hereditary Angioedema (-19.2%) reflect lower sales of CINRYZE (-56.0%) and FIRAZYR (-58.8%) due to stocking in the prior year, fewer patients on CINRYZE, and impact from loss of exclusivity and less utilization of FIRAZYR, partially offset by TAKHZYRO sales in the U.S. In Rare Metabolic (+1.0%), parathyroid hormone, NATPARA (-2.2%) was recalled in the U.S. in September this year due to an issue related to the rubber septum of its cartridge. |
• | PDT Immunology. Underlying revenue of PDT Immunology increased by 3.6% compared to the same period of the previous year. Immunoglobulin product revenue increased by 3.0% driven by the growth across both SCIG (subcutaneous immunoglobulin) and IVIG (intravenous immunoglobulin). Albumin product revenue increased by 16.9%. |
• | Oncology. In Oncology, the year-over-year increase was 10.5%, led by NINLARO (+32.7%) and ADCETRIS (+32.7%). ALUNBRIG also marked a growth rate of 50.7%. The only major Oncology product that declined on an underlying basis was VELCADE (-1.5%) with a 43.8% decrease in ex-US royalty income due to generic entry in Europe in late April. |
• | Neuroscience. In Neuroscience, underlying revenue increased by 5.6% due to the growth of VYVANSE (+5.4%) and TRINTELLIX (+28.1%), both of which are leading branded medications in the U.S. for ADHD and MDD, respectively. ADDERALL XR declined by 38.7% due to greater impacts from generic competition. |
Underlying Revenue Growth*4 by Therapeutic Area | |
GI | +8.9% |
Rare Diseases | -10.5% |
Rare Metabolic | +1.0% |
Rare Hematology | -12.7% |
Hereditary Angioedema | -19.2% |
PDT Immunology | +3.6% |
Oncology | +10.5% |
Neuroscience | +5.6% |
Other | -8.2% |
Total | -0.2% |
• | Revenue of former subsidiaries, Guangdong Techpool Bio-Pharma Co., Ltd. ("Techpool"), and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. ("Multilab"), is excluded from the same period of the prior year consolidated revenue as both subsidiaries were divested in the fiscal year ended March 31, 2019. |
• | Net sales from XIIDRA, the divestiture of which was completed in July 2019, and net sales from TACHOSIL are excluded from both the current period and the same period of the prior year as Takeda agreed in May 2019 to divest these products, with completion of divestiture of TACHOSIL also expected to occur within FY2019. |
2.Outlook for Fiscal 2019 |
Previous Forecast (July 31, 2019) | Revised Forecast (October 31, 2019) | vs. Previous Forecast | vs. Fiscal 2018 | ||||||||||||
Revenue | 3,300.0 | 3,260.0 | (40.0 | ) | +1,162.8 | +55.4 | % | ||||||||
Operating profit | (166.0 | ) | (110.0 | ) | +56.0 | (315.0 | ) | — | % | ||||||
Profit before tax | (342.0 | ) | (290.0 | ) | +52.0 | (384.9 | ) | — | % | ||||||
Net profit for the period (attributable to owners of the Company) | (367.7 | ) | (273.0 | ) | +94.7 | (382.1 | ) | — | % | ||||||
EPS (JPY) | (236.05 | ) | (175.31 | ) | +60.74 | (288.81 | ) | — | % | ||||||
Core Operating Profit* | 910.0 | 930.0 | +20.0 | +470.7 | +102.5 | % |
Billion JPY | ||||||
Fiscal 2018 | Fiscal 2019 | |||||
FX rates | 1 USD = 111 JPY 1 Euro = 129 JPY 1 RUB = 1.7 JPY 1 BRL = 29.5 JPY 1 CNY = 16.5 JPY | 1 USD = 109 JPY 1 Euro = 121 JPY 1 RUB = 1.7 JPY 1 BRL = 26.9 JPY 1 CNY = 15.5 JPY | ||||
R&D expenses | (368.3 | ) | (484.0 | ) | ||
Shire acquisition related costs | ||||||
Operating expenses (acquisition costs, etc.) | (25.3 | ) | (7.0 | ) | ||
Other operating expenses (integration costs) | (59.6 | ) | (146.0 | ) | ||
Financial expenses (interest costs, etc.) | (41.3 | ) | (80.0 | ) | ||
Financial expenses | (83.3 | ) | (172.0 | ) | ||
Impact from Shire's purchase accounting (major items) | ||||||
Cost of sales (unwind of inventory fair value adjustment) | (82.2 | ) | (211.0 | ) | ||
Amortization of intangibles assets (Shire acquisition) | (99.2 | ) | (423.0 | ) | ||
Other non-cash items | ||||||
Amortization of intangible assets (Legacy Takeda) | (95.4 | ) | (93.0 | ) | ||
Impairment losses on intangible assets | (8.7 | ) | (121.0 | ) | ||
Capital expenditures | 244.6 | 180.0 - 230.0 | ||||
Depreciation and amortization (excluding intangible assets associated with products) | (77.2 | ) | (150.0 | ) |
Previous Guidance (July 31, 2019) | Revised Guidance (October 31, 2019) | |
Underlying Revenue Growth* | Flat to slightly increasing | Flat to slightly increasing |
Underlying Core Operating Profit Margin | Mid-to-high-twenties % | High-twenties % |
Underlying Core EPS | 360 - 380 yen | 370 - 390 yen |
Annual dividend per share | 180 yen | 180 yen |
3.Interim Dividend for Fiscal 2019 |
Condensed Interim Consolidated Financial Statements [IFRS] |
JPY (millions) | ||||||||
Six-month period ended September 30, | ||||||||
2018 | 2019 | |||||||
Revenue | 880,611 | 1,660,169 | ||||||
Cost of sales | (231,341 | ) | (572,302 | ) | ||||
Selling, general and administrative expenses | (293,783 | ) | (462,469 | ) | ||||
Research and development expenses | (151,432 | ) | (230,363 | ) | ||||
Amortization and impairment losses on intangible assets associated with products | (48,288 | ) | (273,652 | ) | ||||
Other operating income | 32,331 | 11,316 | ||||||
Other operating expenses | (16,142 | ) | (82,389 | ) | ||||
Operating profit | 171,956 | 50,310 | ||||||
Finance income | 4,411 | 17,370 | ||||||
Finance expenses | (19,618 | ) | (99,268 | ) | ||||
Share of profit of investments accounted for using the equity method | 4,031 | 4,031 | ||||||
Profit (loss) before tax | 160,780 | (27,557 | ) | |||||
Income tax (expenses) benefit | (34,291 | ) | 60,837 | |||||
Net profit for the period | 126,489 | 33,280 | ||||||
Attributable to: | ||||||||
Owners of the Company | 126,668 | 33,184 | ||||||
Non-controlling interests | (179 | ) | 96 | |||||
Net profit for the period | 126,489 | 33,280 | ||||||
Earnings per share (JPY) | ||||||||
Basic earnings per share | 161.76 | 21.32 | ||||||
Diluted earnings per share | 160.93 | 21.25 |
JPY (millions) | ||||||||
Six-month period ended September 30, | ||||||||
2018 | 2019 | |||||||
Net profit for the period | 126,489 | 33,280 | ||||||
Other comprehensive income (loss) | ||||||||
Items that will not be reclassified to profit or loss: | ||||||||
Changes in fair value of financial assets measured at fair value through other comprehensive income (loss) | 13,008 | (9,916 | ) | |||||
Re-measurement loss on defined benefit plans | (163 | ) | (4,612 | ) | ||||
12,845 | (14,528 | ) | ||||||
Items that may be reclassified subsequently to profit or loss: | ||||||||
Exchange differences on translation of foreign operations | 66,680 | (180,311 | ) | |||||
Cash flow hedges | 1,704 | (1,256 | ) | |||||
Hedging cost | (152 | ) | (67 | ) | ||||
Share of other comprehensive income (loss) of investments accounted for using the equity method | (171 | ) | 3 | |||||
68,061 | (181,631 | ) | ||||||
Other comprehensive income (loss) for the period, net of tax | 80,906 | (196,159 | ) | |||||
Total comprehensive income (loss) for the period | 207,395 | (162,879 | ) | |||||
Attributable to: | ||||||||
Owners of the Company | 207,742 | (162,996 | ) | |||||
Non-controlling interests | (347 | ) | 117 | |||||
Total comprehensive income (loss) for the period | 207,395 | (162,879 | ) | |||||
JPY (millions) | ||||||||
As of March 31, 2019 | As of September 30, 2019 | |||||||
ASSETS | ||||||||
NON-CURRENT ASSETS: | ||||||||
Property, plant and equipment | 1,331,932 | 1,457,060 | ||||||
Goodwill | 4,187,006 | 4,029,507 | ||||||
Intangible assets | 4,846,981 | 4,425,199 | ||||||
Investments accounted for using the equity method | 114,658 | 124,708 | ||||||
Other financial assets | 192,241 | 225,870 | ||||||
Other non-current assets | 87,472 | 92,449 | ||||||
Deferred tax assets | 88,991 | 150,908 | ||||||
Total non-current assets | 10,849,281 | 10,505,701 | ||||||
CURRENT ASSETS: | ||||||||
Inventories | 953,474 | 840,840 | ||||||
Trade and other receivables | 741,907 | 779,431 | ||||||
Other financial assets | 23,276 | 13,916 | ||||||
Income tax receivables | 7,212 | 26,306 | ||||||
Other current assets | 109,666 | 104,697 | ||||||
Cash and cash equivalents | 702,093 | 543,517 | ||||||
Assets held for sale | 497,198 | 65,733 | ||||||
Total current assets | 3,034,826 | 2,374,440 | ||||||
Total assets | 13,884,107 | 12,880,141 | ||||||
LIABILITIES AND EQUITY | ||||||||
LIABILITIES | ||||||||
NON-CURRENT LIABILITIES: | ||||||||
Bonds and loans | 4,766,005 | 4,853,219 | ||||||
Other financial liabilities | 235,786 | 409,237 | ||||||
Net defined benefit liabilities | 156,513 | 158,564 | ||||||
Accrued income taxes | 61,900 | 60,159 | ||||||
Provisions | 33,760 | 28,497 | ||||||
Other non-current liabilities | 73,881 | 61,725 | ||||||
Deferred tax liabilities | 869,313 | 804,422 | ||||||
Total non-current liabilities | 6,197,158 | 6,375,823 | ||||||
CURRENT LIABILITIES: | ||||||||
Bonds and loans | 984,946 | 171,391 | ||||||
Trade and other payables | 327,394 | 280,409 | ||||||
Other financial liabilities | 47,340 | 68,658 | ||||||
Accrued income taxes | 118,910 | 175,698 | ||||||
Provisions | 388,920 | 428,634 | ||||||
Other current liabilities | 439,076 | 421,517 | ||||||
Liabilities held for sale | 216,775 | 88,327 | ||||||
Total current liabilities | 2,523,361 | 1,634,634 | ||||||
Total liabilities | 8,720,519 | 8,010,457 |
JPY (millions) | ||||||||
As of March 31, 2019 | As of September 30, 2019 | |||||||
EQUITY | ||||||||
Share capital | 1,643,585 | 1,668,092 | ||||||
Share premium | 1,650,232 | 1,666,141 | ||||||
Treasury shares | (57,142 | ) | (87,082 | ) | ||||
Retained earnings | 1,569,365 | 1,477,589 | ||||||
Other components of equity | 353,542 | 140,974 | ||||||
Equity attributable to owners of the Company | 5,159,582 | 4,865,714 | ||||||
Non-controlling interests | 4,006 | 3,970 | ||||||
Total equity | 5,163,588 | 4,869,684 | ||||||
Total liabilities and equity | 13,884,107 | 12,880,141 |
The companies in which Takeda Pharmaceutical Company Limited (Takeda) directly and indirectly owns investments are separate entities. In this report, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This report and any materials distributed in connection with this report may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see "Item 3. Key Information-D. Risk Factors" in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this report should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this report may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results. Certain Non-IFRS Financial Measures This report includes certain non-IFRS financial measures and targets. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this report. Non-IFRS results exclude certain income and cost items which are included in IFRS results. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda's performance, core results and underlying trends. Non-IFRS results are not prepared in accordance with IFRS and non-IFRS information should be considered a supplement to, and not a substitute for, financial statements prepared in accordance with IFRS. Investors are encouraged to review the reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures. Medical information This report contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. |
Financial information Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). The acquisition of Shire closed on January 8, 2019, and our consolidated results for the fiscal year ended March 31, 2019 include Shire’s results from January 8, 2019 to March 31, 2019. References to "Legacy Takeda" businesses are to our businesses held prior to our acquisition of Shire. References to "Legacy Shire" businesses are to those businesses acquired through the acquisition of Shire. This report includes certain pro forma information giving effect to the acquisition of Shire as if it had occurred on April 1, 2018. This pro forma information has not been prepared in accordance with Article 11 of Regulation S-X. This pro forma information is presented for illustrative purposes and is based on certain assumptions and judgments based on information available to us as of the date hereof, which may not necessarily have been applicable if the acquisition of Shire had actually happened as of April 1, 2018. Moreover, this pro forma information gives effect to certain transactions and other events which are not directly attributable to the acquisition of Shire and/or which happened subsequently to the acquisition of Shire, such as divestitures and the effects of the purchase price allocation for the acquisition of Shire, and therefore may not accurately reflect the effect on our financial condition and results of operations if the acquisition of Shire had actually been completed on April 1, 2018. Therefore, undue reliance should not be placed on the pro forma information included herein. |
Recent Topics |
Fiscal year | April 1 each year to March 31 of the following year | |
Ordinary General Meeting of Shareholders | June each year | |
Reference dates | Ordinary General Meeting of Shareholders | March 31 each year |
Term-end dividend | March 31 each year | |
Interim dividend | September 30 each year | |
Number of shares per share unit | 100 shares | |
Transfer agent and Administrator of the Special Account | 4-5, marunouchi1-chome, Chiyoda-ku, Tokyo Mitsubishi UFJ Trust and Banking Corporation | |
Inquiries | Mitsubishi UFJ Trust and Banking Corporation Osaka Corporate Agency Division 6-3, Fushimimachi 3-chome, Chuo-ku, Osaka 541-8502 0120-094-777 (toll-free number) | |
Methods used for public notices | Electronic public notice Public notices are published on the website: https://www.takeda.com/jp/investors/public-notice/ However, if the Company is unable to make public notices by electronic means due to breakdown or other unavoidable reason, public notices will be published in the Nihon Keizai Shimbun. |
LZ'.K21CUD80QJXD(8H!A&&&F0!!DVH&]M2G/P5J
M4(4Z5*(6U:A'16I2E;I4IMHT;<@XQC1$5@UHA**3EHC$(O*@!C)X@0I+X,$)
M5*"!%